FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943408083> ?p ?o ?g. }

• W2943408083 endingPage "135" @default.
• W2943408083 startingPage "130" @default.
• W2943408083 abstract "Treatments for enthesitis-related arthritis (ERA) consist of a mono- or combination therapy with non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs (DMARDs), and biological agents, and they are primarily based on adult studies and studies on other forms of juvenile idiopathic arthritis, depending on whether there is axial or peripheral involvement. We use DMARDs frequently in our daily practice, even in patients with axial involvement. The main reason for this is that the health insurance system in Turkey does not allow the use of Tumor Negrosis Factor (TNF) blockers as the first line of treatment. The aim of this study is to evaluate the factors affecting the duration of DMARDs application in patients with ERA.Fifty-two patients with ERA were accepted in this retrospective cohort study. These patients did not have an inflammatory bowel disease, reactive arthritis or undifferentiated arthritis, psoriasis, and familial Mediterranean fever. Demographic characteristics, medical history, the initial and follow-up physical examination, initial Juvenile Spondyloarthritis Disease Activity Index (JSpADA), initial laboratory tests, radiographic tests, Juvenile Arthritis Damage Index-articulary (JADI-A) and extra-articulary (JADI-E) on the last admission, and data on medical treatments were recorded from the registered data. The univariate Cox proportional hazards regression analyses was used to determine factors affecting the non-response time of ERA patients to DMARDs before the biological treatment was started.Twenty-seven patients (52%) achieved remission with DMARDs, while 25 (48%) patients did not. The age at diagnosis (HR=1.12; p=0.247); gender (HR=2.53; p=0.210); family history of ankylosing spondylitis (HR=1.17; p=0.730); inflammatory back pain (HR=0.57; p=0.175); the shoulder (HR=0.75 p=0.706), hip (HR=0.45; p=0.129), and small-joint involvement (HR=1.53; p=0.439); sacroiliitis with physical examination (HR=0.90; p=0.814) and magnetic resonance imaging (MRI) (HR=2.84; p=0.110); enthesitis (HR=0.83; p=0.670); presence of uveitis (HR=2.04; p=0.342); presence of HLA-B27 (HR=1.39; p=0.524); initial high acute phase reactants levels(HR=1.89; p=0.183); initial JSpADA score (HR=0.98; p=0.944); and last JADI-A (HR=1.41; p=0.060) score did not affect the duration of DMARDs treatment before switching to biological treatments.In our study, the absence of factors affecting the duration of DMARDs application in patients with ERA showed that DMARDs may still be applied as the first line of treatment." @default.
• W2943408083 created "2019-05-09" @default.
• W2943408083 creator A5010382336 @default.
• W2943408083 creator A5011080603 @default.
• W2943408083 creator A5016347896 @default.
• W2943408083 creator A5019015729 @default.
• W2943408083 creator A5035823526 @default.
• W2943408083 creator A5061188173 @default.
• W2943408083 date "2019-07-25" @default.
• W2943408083 modified "2023-10-01" @default.
• W2943408083 title "Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis" @default.
• W2943408083 cites W1497339122 @default.
• W2943408083 cites W1681879880 @default.
• W2943408083 cites W1970000120 @default.
• W2943408083 cites W1998725696 @default.
• W2943408083 cites W2044081666 @default.
• W2943408083 cites W2052399849 @default.
• W2943408083 cites W2077923057 @default.
• W2943408083 cites W2091811606 @default.
• W2943408083 cites W2100675242 @default.
• W2943408083 cites W2106079991 @default.
• W2943408083 cites W2109519796 @default.
• W2943408083 cites W2115586926 @default.
• W2943408083 cites W2130978342 @default.
• W2943408083 cites W2135974703 @default.
• W2943408083 cites W2147921185 @default.
• W2943408083 cites W2170352055 @default.
• W2943408083 cites W2172018173 @default.
• W2943408083 cites W2221264044 @default.
• W2943408083 cites W2236471049 @default.
• W2943408083 cites W2266653802 @default.
• W2943408083 cites W2410134286 @default.
• W2943408083 cites W2414506117 @default.
• W2943408083 cites W2591102674 @default.
• W2943408083 cites W2802776679 @default.
• W2943408083 cites W2807921027 @default.
• W2943408083 cites W3187992926 @default.
• W2943408083 cites W4211170289 @default.
• W2943408083 cites W763639271 @default.
• W2943408083 doi "https://doi.org/10.5152/eurjrheum.2019.18180" @default.
• W2943408083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6668635" @default.
• W2943408083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31070580" @default.
• W2943408083 hasPublicationYear "2019" @default.
• W2943408083 type Work @default.
• W2943408083 sameAs 2943408083 @default.
• W2943408083 citedByCount "4" @default.
• W2943408083 countsByYear W29434080832020 @default.
• W2943408083 countsByYear W29434080832021 @default.
• W2943408083 countsByYear W29434080832022 @default.
• W2943408083 countsByYear W29434080832023 @default.
• W2943408083 crossrefType "journal-article" @default.
• W2943408083 hasAuthorship W2943408083A5010382336 @default.
• W2943408083 hasAuthorship W2943408083A5011080603 @default.
• W2943408083 hasAuthorship W2943408083A5016347896 @default.
• W2943408083 hasAuthorship W2943408083A5019015729 @default.
• W2943408083 hasAuthorship W2943408083A5035823526 @default.
• W2943408083 hasAuthorship W2943408083A5061188173 @default.
• W2943408083 hasBestOaLocation W29434080831 @default.
• W2943408083 hasConcept C126322002 @default.
• W2943408083 hasConcept C144301174 @default.
• W2943408083 hasConcept C167135981 @default.
• W2943408083 hasConcept C1862650 @default.
• W2943408083 hasConcept C195910791 @default.
• W2943408083 hasConcept C203014093 @default.
• W2943408083 hasConcept C2776260265 @default.
• W2943408083 hasConcept C2777077863 @default.
• W2943408083 hasConcept C2779134260 @default.
• W2943408083 hasConcept C2780131103 @default.
• W2943408083 hasConcept C2780564577 @default.
• W2943408083 hasConcept C38180746 @default.
• W2943408083 hasConcept C50382708 @default.
• W2943408083 hasConcept C71924100 @default.
• W2943408083 hasConcept C72563966 @default.
• W2943408083 hasConceptScore W2943408083C126322002 @default.
• W2943408083 hasConceptScore W2943408083C144301174 @default.
• W2943408083 hasConceptScore W2943408083C167135981 @default.
• W2943408083 hasConceptScore W2943408083C1862650 @default.
• W2943408083 hasConceptScore W2943408083C195910791 @default.
• W2943408083 hasConceptScore W2943408083C203014093 @default.
• W2943408083 hasConceptScore W2943408083C2776260265 @default.
• W2943408083 hasConceptScore W2943408083C2777077863 @default.
• W2943408083 hasConceptScore W2943408083C2779134260 @default.
• W2943408083 hasConceptScore W2943408083C2780131103 @default.
• W2943408083 hasConceptScore W2943408083C2780564577 @default.
• W2943408083 hasConceptScore W2943408083C38180746 @default.
• W2943408083 hasConceptScore W2943408083C50382708 @default.
• W2943408083 hasConceptScore W2943408083C71924100 @default.
• W2943408083 hasConceptScore W2943408083C72563966 @default.
• W2943408083 hasIssue "3" @default.
• W2943408083 hasLocation W29434080831 @default.
• W2943408083 hasLocation W29434080832 @default.
• W2943408083 hasLocation W29434080833 @default.
• W2943408083 hasLocation W29434080834 @default.
• W2943408083 hasLocation W29434080835 @default.
• W2943408083 hasOpenAccess W2943408083 @default.
• W2943408083 hasPrimaryLocation W29434080831 @default.
• W2943408083 hasRelatedWork W1976666740 @default.
• W2943408083 hasRelatedWork W2071065611 @default.

• next